Yusuf Henriques
Trusted by Brands and Start-Ups across the globe
Yusuf N. Henriques is the Founder & Chief Executive Officer (CEO) of IndyGeneUS BIO (pronounced indigenous) a biofintech company that holds exclusive access to the Missing 88%, the African, Indigenous and women’s genomic data every major biobank has left out. Combined with its Clinico-Genomic Insight Engine™ (CGIE™) and sovereign infrastructure, that generates novel disease targets for all humanity across Cancer, Vision Loss, Cardiometabolic, Sickle Cell, Rare Diseases, Neurodegenerative, Veterans Health, Infectious Diseases and BioDefense.
The Jamaican-born immigrant is a serial start-up visionary whose companies are at the helm of technology and thrive at the intersection of financial and health equity. He is passionate about mentoring the next generation of founders and was a 2022 Techstars Mentor-In-Residence.
Henriques is a sought after thought leader where he frequently speaks on the importance of precision health equity and the power of Whole Genome Sequencing (WGS), with an emphasis on BIPOC communities.
Prior to Henriques’ start-up ventures he was a sought after regulatory affairs expert. He launched his career in the regulatory space as the acting Branch Chief for the Ob/Gyn, Gastroenterology, and Urology Divisions in the Center for Device and Radiological Health at the Food & Drug Administration (FDA).
He served as Director of Regulatory Affairs for SAIC, where he oversaw regulatory compliance strategies for multi-site clinical trials. He was a lead regulatory scientist for the Strategic Innovation Group (SIG) at Booz Allen Hamilton and Senior Research Health Scientist for Outpatient Psychiatry at the James J. Peters Veteran Affairs Medical Center in The Bronx, NY.
Henriques managed a $45M scientific portfolio for a large multi-center clinical trial research project in PTSD and TBI (Traumatic Brain Injuries) for the VA Cooperative Study Research Program and the Department of Defense, where he studied alongside Rachel Yehuda, the Vice-chair of Icahn School of Medicine at Mount Sinai (ISMMS) Psychiatry Department. It was through his association with ISMMS that he gained exclusive rights to the patent for the PTSD genomic assay (TruGen-1) that he developed under his first start-up TruGenomix (Polaris Genomics). The patent is currently being piloted at the Department of Veteran Affairs (VA) hospitals nationwide to address the high rate of suicides in the veteran and active-duty populations.
The Howard University graduate earned his Bachelor of Science in Biochemistry (Magna Cum Laude) and 95% of his IndyGeneUS team are also Howard Alum. He is a proud father of four girls, an avid LinkedIn contributor, and a lover of soccer.
Let’s Stay Connected
Complete the form below to submit an inquiry or to book Mr. Henriques for your next speaking engagement.